Kilitch Drugs (India) Ratios

Kilitch Drugs (India) Ltd Ratios

The Kilitch Drugs (India) Ltd Ratios page provides a complete fundamental analysis of Kilitch Drugs (India) Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Kilitch Drugs (India) Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Kilitch Drugs (India) Ltd (NSE: KILITCH, BSE: 524500) is currently trading at ₹317.90, with a market capitalization of ₹5.59B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Kilitch Drugs (India) Ltd remains a key stock for fundamental analysis using Kilitch Drugs (India) Ltd Ratios.

Kilitch Drugs (India) Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Kilitch Drugs (India) Ltd P/E ratio currently stands at 21.77, making it one of the most tracked metrics in Kilitch Drugs (India) Ltd Ratios.

Historically, the Kilitch Drugs (India) Ltd P/E ratio has shown strong fluctuations:

• 2024: 21.77
• 2023: 42.53
• 2022: 20.81
• 2021: 35.43
• 2020: 34.18

The decline in Kilitch Drugs (India) Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Kilitch Drugs (India) Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.87.

Historical P/B trend:

• 2024: 2.87
• 2023: 3.56
• 2022: 1.43
• 2021: 1.88

Kilitch Drugs (India) Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Kilitch Drugs (India) Ltd P/S ratio currently stands at 2.93, an important part of Kilitch Drugs (India) Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.93
• 2023: 4.02
• 2022: 1.56
• 2021: 2.29

A stable or declining Kilitch Drugs (India) Ltd P/S ratio indicates cautious market sentiment.

Kilitch Drugs (India) Ltd Price to Cash Flow Ratio (P/CF)

The Kilitch Drugs (India) Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 42.95.

Historical Kilitch Drugs (India) Ltd Price to Cash Flow Ratio:

• 2024: 42.95
• 2023: 0
• 2022: 0
• 2021: 43.28
• 2020: 2.78

The rising Kilitch Drugs (India) Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Kilitch Drugs (India) Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Kilitch Drugs (India) Ltd EV currently stands at ₹5.69B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 5.69B
• 2023: 5.83B
• 2022: 1.79B
• 2021: 2.25B

Kilitch Drugs (India) Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Kilitch Drugs (India) Ltd EV/EBITDA ratio is currently 17.72, a key metric in Kilitch Drugs (India) Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 17.72
• 2023: 23.59
• 2022: 9.93
• 2021: 19.68

Stable Kilitch Drugs (India) Ltd EV/EBITDA indicates balanced valuation.

Kilitch Drugs (India) Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Kilitch Drugs (India) Ltd D/E ratio is currently 0.24, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.24
• 2023: 0.18
• 2022: 0.15
• 2021: 0.15

Kilitch Drugs (India) Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Kilitch Drugs (India) Ltd ROE currently stands at 14.10%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 14.10
• 2023: 8.91
• 2022: 7.19
• 2021: 5.53

Kilitch Drugs (India) Ltd maintains stable profitability levels.

Kilitch Drugs (India) Ltd Ratios Analysis Summary

The Kilitch Drugs (India) Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Kilitch Drugs (India) Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Kilitch Drugs (India) Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.